What You Should Know: 

– RFX Solutions, a leading provider of SaaS compliance software for healthcare facilities, has announced a successful $9 million Series A funding round led by Arthur Ventures. 

– The user-friendly SaaS platform empowers healthcare facilities to navigate the complexities of regulatory requirements efficiently and effectively. This investment by Arthur Ventures positions RFX Solutions to become an even more dominant force in the healthcare compliance landscape, ultimately leading to a future where streamlined processes and reduced risks allow healthcare professionals to prioritize what matters most – patient care.

Addressing a Critical Pain Point

Manual management of compliance data and documents remains a major burden for healthcare facilities. This traditional approach is prone to errors, inefficiencies, and risks associated with non-compliance. Facilities often struggle with document mismanagement and spend excessive time preparing for audits and surveys.

RFX Solutions: A Streamlined Future for Healthcare Compliance

RFX Solutions offers a revolutionary solution. Their innovative SaaS platform tackles these challenges head-on, paving the way for a future where:

• Compliance is streamlined: RFX’s software automates and simplifies compliance processes, freeing up valuable time and resources.
• Risks are minimized: With organized data and efficient workflows, the risk of non-compliance and errors is significantly reduced.
• Focus is back on patient care: By alleviating the burden of compliance tasks, healthcare professionals can dedicate more time and energy to delivering exceptional patient care.

“We are thrilled to partner with Arthur Ventures, a firm that truly understands the SaaS landscape and shares our vision for a more efficient and error-free compliance process in healthcare. This investment is not just a financial milestone but a testament to the hard work and dedication of our team. It propels us forward in our mission to eliminate the cumbersome and error-prone manual management of compliance data and documents in healthcare facilities,” said Amanda Penrod, PhD, Co-Founder & CEO of RFX Solutions.

What You Should Know: 

– Two Chairs, a leading innovator in behavioral health, has announced the closing of a $72 million Series C funding round led by Amplo with participation from Fifth Down Capital and others, bringing Two Chairs’ total capital raised to $103 million. 

– Founded in 2017, Two Chairs is dedicated to creating a world where everyone has access to exceptional mental healthcare. They are recognized as a top employer for therapists, boasting over 500 licensed professionals with expertise in 90 areas. 

– The new funding fuels the company’s ambitious mission of making exceptional mental healthcare more accessible and effective nationwide.

Matching Clients with the Perfect Therapist

Two Chairs takes therapist-client matching to the next level. Their proprietary 300-variable algorithm, combined with a “matching consult” led by a licensed clinician, ensures clients connect with the right therapist for their specific needs. This personalized approach is reflected in the impressive statistic: 97% of Two Chairs clients report a strong alliance with their therapist, setting the stage for successful treatment.

Data-Driven for Personalized Care

Two Chairs goes beyond matching. Their leading approach to measurement-based care leverages real-time data to track client progress and well-being. This data empowers therapists to personalize treatment plans, strengthen the therapeutic connection, and ultimately help clients achieve their goals faster.

Investing in Therapists: A Key Differentiator

Recognizing the importance of well-supported and satisfied therapists, Two Chairs prioritizes a differentiated full-time clinician experience.  They offer a hybrid care model with both in-person and virtual therapy options across multiple locations in California, Washington, and Florida, with expansion into additional states planned within the next year.

Insurance Coverage and Future Partnerships

Two Chairs operates within an in-network model, partnering with major insurance providers like Aetna nationally and Kaiser Permanente in Washington and Northern California. This allows patients to access high-quality therapy with just a copay or coinsurance. Further healthcare partnerships are expected to be finalized throughout 2024.

“Two Chairs epitomizes quality in behavioral health, taking an extraordinarily thoughtful approach, and you can see it in their outcomes data,” said Sheel Tyle, Founder & CEO of Amplo. “Industry-wide, only about a third of patients progress to their fourth therapy session, whereas for Two Chairs, 90% of their patients do. We proudly invest in thriving companies where quality is a core advantage. Two Chairs has been growing quickly—in all the right ways and for all the right reasons.”

What You Should Know: 

– Kontakt.io, a leading innovator in Inpatient Journey Analytics, has announced a significant investment of $47.5 million. This Series C funding round, led by Growth Equity at Goldman Sachs Asset Management (Goldman Sachs), empowers Kontakt.io to accelerate its growth and fuel the expansion of its cutting-edge Artificial Intelligence (AI) solutions.

– Goldman Sachs’ investment signifies their confidence in Kontakt.io’s disruptive technology and market potential. Christian Resch, a partner at Goldman Sachs, will join Kontakt.io’s Board of Directors, providing valuable guidance and expertise to fuel the company’s next phase of growth.

Addressing Critical Challenges in Hospital Operations

The need for operational excellence in hospitals has never been greater. The healthcare industry faces:

• Increasing Complexity: Managing patient flow, resource allocation, and staff scheduling presents growing challenges.
• Rising Cost Burdens: Hospitals are constantly seeking ways to optimize resource utilization and reduce waste.
• Employee Attrition: High staff turnover rates can disrupt workflows and negatively impact patient care.

Inefficiencies in hospital care delivery are estimated to cost the US healthcare system roughly $300 billion annually. Kontakt.io’s AI-powered platform tackles these challenges head-on, empowering hospitals to deliver better care while minimizing waste.

Optimizing Patient Care with Real-Time Data

Kontakt.io is transforming hospital operations by harnessing the power of AI, the Internet of Things (IoT), and cloud technology. Their platform provides:

• Real-time location data: Tracks patients, staff, and equipment, offering valuable insights into workflow optimization.
• Orchestrated Resource Management: Streamlines staff deployment, equipment allocation, and utilization of clinical spaces around the patient’s care journey.

By seamlessly integrating these technologies into existing workflows, Kontakt.io is paving the way for a new era of operational excellence in clinical care delivery. This data-driven approach fosters:

• Improved Safety and Coordination: Enhanced visibility into patient location and resource allocation minimizes potential errors and delays.
• Elevated Patient and Staff Experiences: Streamlined processes create a more efficient and positive environment for both patients and healthcare professionals.
• Rapid Return on Investment (ROI): Hospitals leveraging Kontakt.io’s platform have documented significant improvements in operational efficiency, leading to cost savings.

Proven Success in Leading Healthcare Institutions

Kontakt.io’s solutions have demonstrably improved outcomes for renowned healthcare systems, including HCA, the VA, Mercy Health, North East Georgia Health System, Trinity Health, and the NHS.

“Clinical staff, the key asset of health systems, must be freed to focus on their single most important job: providing patient care,“ commented Philipp von Gilsa, CEO of Kontakt.io. “Our partnership with Goldman Sachs will help Kontakt.io further expand into AI to orchestrate care delivery resources and processes, putting staff and patients back at the center of care.”

What You Should Know: 

– Sunstone Partners, a leading private equity firm, has announced a strategic investment in Accuhealth, a prominent healthcare technology company. 

– The investment aims to propel Accuhealth’s rapid growth and empower them to expand their remote patient monitoring (RPM) and chronic care management (CCM) solutions.

A Focus on Simplifying Remote Patient Care

Accuhealth offers a comprehensive suite of hardware, software, and clinical monitoring solutions for RPM and CCM. Their focus lies in simplifying this technology for both healthcare providers and patients, ultimately enhancing primary physician care delivery.

The cornerstone of Accuhealth’s solution is providing real-time access to patient vitals. This empowers physicians to:

• Improve patient outcomes by proactively monitoring trends and identifying potential health issues early on.
• Enhance patient experience through more informed care decisions and potentially fewer in-person appointments.
• Reduce overall healthcare costs by preventing complications and hospital readmissions.

“We are thrilled to welcome Sunstone Partners as a strategic partner in our journey to redefine healthcare through innovation,” said Stephen Samson, CEO and Co-Founder of Accuhealth. “This investment marks a pivotal moment for Accuhealth, enabling us to accelerate our growth trajectory and further enhance our RPM and CCM solutions. With Sunstone Partners’ support, we are poised to drive greater value for our clients, attract top talent, and ultimately improve patient outcomes. Together, we will continue to lead the way in revolutionizing the delivery of healthcare.”

What You Should Know:

–              Ilant Health, a pioneering leader in value-based obesity management and cardiometabolic health solutions, announced today the extension of its seed round of fundraising from $3 million to $5.5 million.

–              The women-led startup received additional funds from a combination of new health-oriented investors, including funds from LifeX Ventures, Celtic House Asia Partners, and Cornucopian Capital, as well as existing investors reaffirming their commitment to Ilant Health’s transformative mission.

Ilant Health: Pioneering Innovation in Obesity Treatment and Healthcare Financing

Ilant Health’s decision to extend its seed round arises amid its accelerating traction propelled by a robust clinical model and proprietary analytics. Notably, Ilant Health has achieved significant recognition, securing accolades such as all three World 50 Group Academies — EHIR, HPIR, and PHIR — and selection for Highmark and Allegheny Health Network’s accelerator, AlphaLab Health. Moreover, the company recently clinched the Employee Health Innovation Roundtable (EHIR) Traction Award, acknowledging its status as the company generating the highest level of interest from EHIR employer members.

Dr. Jeffrey Cohen, Chief Physician Executive at Allegheny Health Network, remarked, “AlphaLab Health looks for companies to solve problems facing healthcare today. Obesity is a major healthcare problem without an organized market approach to solving it. Ilant’s team incorporated behavioral modification, medical and surgical therapies into an organized approach utilizing their proprietary algorithm to tailor the best answer for each patient. We believe they will have a bright future helping provider and payor systems solve this critical healthcare need.”

Ilant Health attributes much of its success to the pivotal roles played by women in its development. Elina Onitskanky, CEO of Ilant Health, founded the company aware of the gender gap in venture capital funding, where only 2% of funding goes to women founders. Nevertheless, Ilant has thrived with steadfast support from healthcare and other women leaders and investors, contributing significantly to its present stature.

Elina, a Harvard Business School graduate, garnered support from several alumnae during the company’s growth. Her colleague Jessica Muse, recognizing its potential as an angel investor, joined as a co-founder and Chief Operating Officer in the company’s early days. Rika Christanto, Partner of LifeX Ventures, identified the vision for Ilant Health and demonstrated confidence by investing $2 million. Similarly, Chrissie Francona, acting as a scout for Pillar Ventures, recognized the startup’s potential and extended support through investment.

Ilant Health’s ongoing commercial traction is evidenced by the successful launch of clinical services to multiple employers and the utilization of its claims analytics for hundreds of thousands of lives on behalf of large health plans and employers. Ilant’s claims analytics, driven by unstructured machine learning, have yielded notable insights into potential reductions in total cost of care and return on investment from obesity treatment.

Outcomes from Ilant’s clinical care to date underscore its ability to engage individuals with the greatest need for care, including those with higher BMIs and medical comorbidities, all while maintaining a world-class Net Promoter Score (NPS). Ilant supports its members in understanding and selecting optimal treatment options – many of which are not GLP-1s – and then provides exceptional integrated care through obesity medicine physicians, dietitians, and mental health specialists.

As part of this fundraising initiative, Ilant has enlisted prominent industry advisors, including Teri Wisness, former Director of U.S. Benefits at Google and Partner at Iron Street Advisors, and Meghan Fitzgerald, former executive at Cardinal Health and member of the Board of Directors at Tenet Healthcare. Wisness commented, “When I met the Ilant team, I was impressed by how they are bringing something new to the obesity treatment market – truly solving employer needs by addressing both utilization management and care provision, recognizing the need.”

What You Should Know:

–              When developing new drugs, nutritional products, or pesticides, it’s critical that unknown molecules are identified correctly. But accurate identification is a lengthy process and all too often unsuccessful, leading to failed regulatory processes, or worse, consumer health being put in danger.

–              Isospec Analytics has raised $1.9M to commercialize new technologies for molecular analysis that rapidly identify unknown molecules in minutes, helping pharmaceuticals, nutrition and agritech companies develop safer products and enabling researchers to discover new biomarkers.

Isospec: Redefining Molecular Analysis for Breakthroughs in Biotech

Founderful (formerly Wingman Ventures) leads Isospec’s $1.9M pre-seed round, joined by specialized investors Tiny.vc, another.vc, and Venture Kick.

Founded in 2022 by Ahmed Ben Faleh, Stephan Warnke, and Thomas Rizzo, Isospec aims to redefine molecular analysis, unlocking new biological insights for diagnostics, therapeutics, and nutrition. Leveraging over 20 years of research, the founders merged technologies from analytical chemistry, photonics, and cryogenic materials originally developed for space applications. This fusion resulted in a groundbreaking tool capable of unveiling previously unknown molecular structures.

Traditional methods of identifying molecules, primarily relying on mass analysis, often fall short. Mass alone cannot definitively determine a molecule’s structure, leading to a time-consuming process of purification and synthesis. Isospec’s technology overcomes this limitation by generating comprehensive metrics that rapidly identify unknown molecules, revolutionizing molecular identification with scalability and speed.

By integrating infrared analysis directly into mass spectrometry, Isospec enhances molecule identification, enabling swift and precise analysis in minutes rather than months. Originating from EPFL’s Laboratory of Molecular Physical Chemistry, their technology is already revolutionizing quality control and R&D in the food and agritech industries.

Currently focused on platform scalability, Isospec is introducing automation and machine learning tools for enhanced data analysis. Positioned within the competitive landscape of sugar and metabolite analytics, Isospec aims to lead the way in molecular analysis and biomarker discovery for therapeutics and diagnostics.

What You Should Know: 

– LunaJoy Health, a FemTech company dedicated to improving women’s mental health, has announced the launch of LunaCare, a novel integrated care program specifically focused on maternal mental health. 

– The initiative is backed by $4.2M in fresh funding from a distinguished group of investors, including Y Combinator, FoundersX Fund, and Goodwater Capital.

Addressing Disparities and Transforming Care

LunaJoy Health’s mission is to eliminate disparities in women’s mental healthcare, particularly for underserved communities. The launch of LunaCare aligns perfectly with this goal, aiming to improve outcomes in maternal mental health. This initiative is especially timely, coinciding with the Centers for Medicare & Medicaid Services’ (CMS) upcoming launch of the Transforming Maternal Health Model (TMaH). This government program aims to bolster infrastructure and improve maternal mental healthcare quality and safety for vulnerable populations.

LunaCare: A Natural Extension of National Efforts

LunaCare is a natural extension of the TMaH program’s goals. It provides a conduit to reach more communities of color by offering a tech-enabled care model that extends beyond traditional brick-and-mortar limitations. LunaCare empowers primary care physicians to address their patients’ mental health needs directly within their existing workflow. This is achieved through LunaJoy’s platform and services, creating a seamless integration of mental healthcare into routine primary care.

Financial Backing Fuels Expansion and Innovation

The recent funding empowers LunaJoy Health to strategically roll out LunaCare across select communities, with plans for further expansion into new markets. Additionally, these resources will be used to integrate advanced technological solutions. These advancements aim to enhance care coordination, patient monitoring, and ultimately ensure mothers receive timely and personalized mental health care.

Availability & Insurance Coverage

LunaJoy Health currently partners with over 15 insurance payers and operates in more than a dozen states. This extensive network positions them to deliver LunaCare to a significant portion of the population in need.

“The support from our investors, coupled with the current focus on maternal health improvements through TMaH funding, sets the stage for the change we so badly need to see across the industry,” said Sipra Laddha, CEO of LunaJoy Health. “Mental health is a lifetime pursuit, and we want to design a way to engage and support women with a variety of needs and varying degrees of risk. By using technology, we can measure and treat symptoms more effectively, delivering a better service model to meet rising demand and a shortage of therapists in the U.S.”

What You Should Know: 

– Elucent Medical, a leader in surgical navigation with its In-Site Spatial Intelligence (iSI) technology raises $42.5M in Series C funding, led by Vensana Capital and RC Capital with participation from existing investors.

– This significant investment will fuel the development and commercialization of Elucent’s innovative EnVisio® and SmartClip® technologies, designed to improve precision and effectiveness in cancer surgery.

Pioneering In-Site Spatial Intelligence

Elucent’s flagship technologies, EnVisio® and SmartClip®, provide surgeons with real-time, in-situ (within the body) spatial intelligence during critical operations. EnVisio® utilizes proprietary technology to transform standard surgical instruments into “smart” tools. These smart tools can be tracked in real-time and guided with millimeter precision, enabling surgeons to operate with greater accuracy.

EnVisio®: Beyond Breast Cancer

While EnVisio® is currently optimized for breast cancer surgery, its platform is expanding to address other soft-tissue oncology procedures. Elucent is also developing additional products using the iSI platform to assist surgeons in achieving margin-negative resections (complete removal of cancerous tissue) in lung and other soft tissue surgeries. These new products seamlessly integrate with existing surgical tools and minimally invasive solutions, including video-assisted and robotic-assisted surgical technologies.

“We are proud to have secured this substantial funding, which will advance our mission to radically change the way surgeons mark and locate their intended target for removal by turning their existing surgical instruments into intelligent tracking devices that elevate the standard of care in soft tissue oncologic procedures,” says Jason Pesterfield, President and CEO of Elucent Medical. “With the support of our investors, we are poised to accelerate the commercialization of our EnVisio^® and SmartClip^® technologies, empowering healthcare providers with innovative tools to improve patient outcomes.”

What You Should Know: 

– Define Ventures, the leading early-stage investor in digital health companies, announced today the appointment of Frank Williams as Venture Partner. 

– Williams, a seasoned entrepreneur and healthcare executive, brings a wealth of experience to the firm, playing a key role in supporting and scaling their portfolio companies.

Williams Bio/Background

Williams boasts an impressive career in healthcare, highlighted by his co-founding role at Evolent Health.  During his tenure as CEO and Chairman, Evolent completed an IPO, achieved over $1 billion in annual revenue, and served more than 15 million patients.  Prior to Evolent, Williams served as Chairman and CEO of The Advisory Board Company, leading them through another successful IPO and significant revenue growth.

Williams’ current commitments demonstrate his continued dedication to healthcare innovation. He sits on the boards of influential companies like Helix, Nayya, and Wellth, and holds leadership positions at UCSF, ICER, and Brown University.

Define Ventures: Investing in the Future of Digital Health

With $800 million in assets under management, Define Ventures partners with digital health companies at various stages, from incubation to Series B funding.  They are known for their “high conviction, hands-on approach,” offering entrepreneurs a valuable network and expertise to drive tangible results.  Define Ventures has partnered with over 20 companies, including industry leaders like Hims & Hers and Unite Us.

What You Should Know: 

– Grow Therapy, a mental health technology company focused on provider-centric care, raises $88M in Series C funding led by Sequoia Capital. The round included participation from Growth Equity at Goldman Sachs Alternatives, PLUS Capital, and a unique group of celebrity investors including Anna Kendrick, Lily Collins, and prominent athletes.

– The funding fuels Grow Therapy’s mission to make high-quality mental healthcare accessible to all.

Building a More Accessible Mental Healthcare System

Grow Therapy is a comprehensive platform to improve access to high-quality mental healthcare.  Their three-sided approach provides integrated solutions for patients, providers, and payers:

• Patients: Grow Therapy offers seamless therapist matching, insurance billing support, secure electronic health records (EHR), and telehealth capabilities.
• Providers: Therapists on the platform benefit from features like patient matching, in-session telehealth support, streamlined EHR with note-taking tools, and access to a supportive professional community.
• Payers: Grow Therapy partners with insurers to offer value-based care models, ensuring cost-effective and high-quality mental health services for covered populations, including Medicaid and Medicare members.

Introducing the Next Generation of Mental Healthcare Technology

Grow Therapy is unveiling significant advancements to its platform, including:

• Seamless Telehealth Infrastructure: Integrated with the Grow Therapy EHR, this new system allows therapists to manage treatment plans, goals, and notes directly within the telehealth platform.
• Enhanced Measurement-Informed Care: This best-in-class system gathers and analyzes clinical assessments, providing visualizations and data-driven prompts to support high-quality care decisions.
• Streamlined Note-Taking: Grow’s EHR system received major upgrades, offering customizable workflows, treatment plan prompts, and functionalities aligned with leading measurement-informed care protocols.
• Advanced Patient Matching: Grow Therapy’s matching algorithm has been refined to ensure optimal compatibility between patients and therapists. Factors considered include therapist availability, specialty, diversity, and most importantly, care quality.
• Expanded Support for Providers: Grow Therapy is investing in its clinical excellence program, offering therapists ongoing learning opportunities and fostering a supportive community for professional growth and collaboration.

A Track Record of Success

Since its founding in 2020, Grow Therapy has achieved impressive results:

• Over 3 Million Patient Encounters: 94% of these encounters were conducted within a patient’s insurance network.
• Industry-Leading Patient Satisfaction: Grow Therapy boasts an 85 Net Promoter Score and delivers clinically significant symptom reduction for moderate to severe cases (around 50%).
• Trusted by Therapists: Over 12,000 therapists across various specialties and backgrounds have joined the platform, with a focus on diversity (44% BIPOC representation). Services are available both in-person and via telehealth across 20 states, with plans for further expansion.
• Strong Payor Network: Grow Therapy collaborates with over 75 insurers, offering tailored services to meet the needs of each health plan and its members.

“Our team believes that empowering people to find and engage with effective mental health support – regardless of their background, geography or financial circumstances – is the most pressing need of our time. The two announcements we’ve made today, including the close of our $88 million Series C from Sequoia Capital and Goldman Sachs Alternatives and the launch of our new measurement-informed care system, represent tremendous strides in helping us fulfill that goal. Together with our partners and stakeholders, we are building an environment where people can easily find care they can trust and afford, and where therapists can serve their communities while building sustainable, rewarding careers,” said Grow Therapy CEO Jake Cooper.

What You Should Know: 

– rater8, a healthcare reputation management and patient feedback platform announced today the successful closing of their Series A funding round led by Elsewhere Partners. 

– The Series A investment will fuel rater8’s growth, allowing them to expand their reach, strengthen partnerships, and enhance their award-winning software-as-a-service (SaaS) solutions.

Capitalizing on the Growing Importance of Online Reputation

The global online reputation management market is expected to surpass $746 million by 2031, with healthcare playing a central role. As patients increasingly turn online to research providers, positive online reviews have become the single most influential factor in their choices. Dissatisfaction with healthcare quality and a rising tendency to switch providers further highlight the critical need for strong online reputations.

rater8: Delivering Unmatched Results for Healthcare Providers

rater8 boasts a proven track record, generating an average 240% increase in annual reviews for over 750 healthcare organizations. Their platform empowers providers to:

• Build Online Visibility: Increase online presence and attract new patients through a robust online reputation.
• Manage Reputation: Proactively monitor and address online reviews, maintaining a positive patient perception.
• Improve Patient Satisfaction: Gather valuable patient feedback to identify areas for improvement and optimize the patient experience.
• Enhance Operational Performance: Leverage data-driven insights to streamline operations and deliver better care.

Seamless Integration and Actionable Insights

Unlike generic review tools, rater8 seamlessly integrates with over 100 electronic health record (EHR) and practice management (PM) systems. They focus on healthcare-specific review sites like Google, Healthgrades, Vitals, and WebMD, ensuring reviews reach the right audience. Additionally, rater8 offers comprehensive analytics that provide healthcare providers with:

• Granular Feedback: Detailed insights into patient satisfaction across individual providers, specialties, practices, and facilities.
• Real-Time Reporting: Access to up-to-date data on a range of patient satisfaction metrics and online review statistics.
• Intelligent Prioritization: An automated system that prioritizes review sites in need of more attention.

“As the healthcare sector evolves, healthtech innovators are clamoring to carve out their niche in an increasingly crowded space. Many will fail, but those who thrive will transform patient experience and practice management. rater8 has grown into a formidable leader in the patient management evolution – building a solution that addresses core industry pain points, growing an incredibly satisfied customer base and continuously outperforming competitors that simply can’t stack up,” said Michele Perry, operating partner, Elsewhere Partners. “The patient feedback market is ready for disruption. We see tremendous opportunity for growth as rater8 further broadens the capabilities of its platform and grows its team to support demand. I have no doubt that the rater8 team will continue to raise the bar for patient feedback solutions and help drive better outcomes for both practices and patients.”

What You Should Know: 

– HealthArc, a virtual healthcare company secures $5M in funding led by ScOp Venture Capital to transform healthcare through its advanced care management platform.

– HealthArc provides a comprehensive suite of virtual care programs and ensures seamless integration with existing systems to empower healthcare providers to deliver exceptional care to their patients.

Unified Care Management Platform

HealthArc’s Unified Care Management Platform offers a comprehensive suite of virtual care solutions:

• Remote Patient Monitoring: Tracks patient health data remotely.
• Remote Therapeutic Monitoring: Monitors specific health conditions remotely.
• Chronic Care Management: Provides ongoing support for patients with chronic conditions.
• Principal Care Management: Manages a patient’s primary care needs.
• Transitional Care Management: Ensures smooth care coordination between healthcare settings.
• Behavioral Health Integration: Integrates behavioral health support into overall care plans.

• Device Connectivity: Integrates with over 50 medical devices from various brands.
• EHR and API Integration: Works seamlessly with top electronic health records (EHRs) and external APIs.
• Onboarding and Training: Facilitates easy adoption for healthcare providers.

What You Should Know:

– Biolinq, a provider of precision wearable biosensors for metabolic health secures $58M led by Alpha Wave Ventures. The round will include participation from Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures and existing investors RiverVest Venture Partners, AXA IM Alts, Global Health Investment Corporation, Aphelion Capital, Senvest Management, Features Capital and Taisho Pharmaceutical. J.P. Morgan served as a placement agent to Biolinq in connection with the financing.

– The funding will propel Biolinq towards completion of a pivotal clinical trial in the US and subsequent FDA submission for its innovative continuous glucose monitoring (CGM) patch.

Biolinq’s Intradermal Sensor

The Biolinq patch offers a unique approach to glucose monitoring:

• Simple and Discreet: Worn on the upper forearm, the patch features an intuitive display for easy blood sugar level tracking.
• Intradermal Sensors: Tiny sensors placed just under the skin measure glucose levels, eliminating the need for finger pricking.
• Multi-Analyte Potential: Biolinq’s sensor array is designed to go beyond glucose monitoring, offering the potential for broader metabolic health insights in the future.
• Redundancy and Reliability: The design incorporates multiple sensors on a single chip, ensuring data accuracy and reliable performance.

Biolinq’s intradermal sensor is currently an investigational device, awaiting FDA clearance.  This new funding positions Biolinq to complete the crucial clinical trial phase and potentially gain FDA approval later this year.

“Our technology approach enables access to a coveted, metabolically active compartment of the skin for biosensing without the use of introducer needles or bleeding,” said Rich Yang, CEO, Biolinq. “Over the past decade, our team has been pioneering a new biosensor platform designed to inform and inspire, with a mission to reach more people that are in need of simple solutions to improve metabolic health.”

What You Should Know:

– Manifold, an AI-powered clinical research platform raises $15M in a Series A funding round led by TQ Ventures with participation from Calibrate Ventures, SK Ventures, and existing investors TTCER Partners and Dr. Sachin H. Jain.

– By accelerating research progress, Manifold paves the way for faster development of life-saving treatments and improved patient outcomes.

AI-Powered Clinical Research Platform

Manifold tackles a critical challenge in medical research: slow and inefficient workflows. Legacy data management systems hinder research progress, delaying breakthroughs that could improve patient outcomes. Manifold’s AI platform tackles this issue head-on by:

• Streamlining Workflows: Automating manual tasks associated with study management and data collection frees up researchers’ time for high-impact work.
• Rapid Insights Generation: Manifold reduces the time needed to extract valuable insights from research data, accelerating the pace of discovery.
• Unified Data Management: The platform integrates complex patient data sets, creating a comprehensive view for researchers.
• Enhanced Collaboration: Secure, multi-institutional collaboration features empower researchers to work together seamlessly.

Client & Outcomes

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center and Winship Cancer Institute of Emory University are among the institutions leveraging Manifold’s platform. One research organization successfully unified a massive 11 terabytes of patient data from 1.5 million individuals onto a single platform. This not only streamlined operations but also unlocked new possibilities for large-scale collaborative research.

“Manifold is transforming clinical research by providing research organizations with purpose-built technology infrastructure for this new era,” said Vinay Seth Mohta, CEO and Co-Founder of Manifold. “Our vision is to make it ten times faster and one-tenth the cost to conduct modern research studies that unlock insights never-before possible.”

What You Should Know:

• Beanstalk Benefits today launched the first benefits platform to give individual employees the access and control to build their own portfolios of “everyday” benefits. 
• By giving employees the flexibility to choose their own health, wealth and wellbeing services and solutions, rather than choosing on their behalf, employers are now better able to meet the dynamic needs of each member of their diverse and modern workforces – all under a single contract.

Beanstalk Benefits: Simplifying and Optimizing Employee Benefits Management

Beanstalk consolidates top-tier benefits services into a comprehensive suite covering mind, body, lifestyle, family, and financial needs. Through its intuitive platform, employees can customize their benefit portfolios, utilizing either employer-sponsored or personal accounts. The suite caters to the diverse workforce, spanning five generations, with solutions ranging from health management to parenting, elder care, finance, and mental well-being. Initial suite members include BeMe for teen well-being, Upswing Health for on-demand pain relief, Vitalxchange for parenting resources, and Sober Sidekick for sobriety support.

Beanstalk Benefits streamlines the complexity of benefits options by providing:

1. Access and Flexibility: Employees gain direct access to a wide array of benefits services and solutions, managing their portfolios effortlessly on an adaptable platform. This enables employers to offer benefits that better suit their diverse workforce, including virtual health solutions for underserved areas.

2. Simplified Contracting: Beanstalk handles all contracts, vendor relations, and customer service, continuously updating its suite with new market entrants. Employers sign one contract and pay an annual fee for access to all solutions.

3. Increased Uptake: Employees are empowered to choose and manage their benefits, enhancing engagement. Beanstalk personalizes communication and updates employees on relevant options.

4. Cost Optimization: Beanstalk’s data analytics tool provides employers with insights to optimize spending, ensuring resources are allocated efficiently based on employee needs.

“We saw a gap because people’s needs often shift during the year, after open enrollment. But typical benefits programs aren’t flexible, and they don’t give busy employees a way to easily find resources and adapt their own portfolios to personal circumstances,” said Matthew Sydney, CEO of Beanstalk. “At the same time, we’re talking to employers that are worn out evaluating employee needs against thousands of benefits offerings. Even the most well-meaning can’t sign enough vendor contracts to create a single benefits package that fits every individual well. Beanstalk lets employers put the benefits decision-making into individual employees’ hands, while employers get aggregated, apples-to-apples data on how employees use their benefits.”